Financials in USD. Standardized financial statements.
A compact view of how Nemaura Medical Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $77,044 | $503,906 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -84.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.55M | $344,300 | $98,075 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | -$1.48M | $159,606 | -$98,075 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | -1916.3% | +31.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $8.12M | $7.73M | $4.59M | $4.78M | $4.48M | $1.91M | $1.55M | $1.54M | $1.32M | $586,233 |
| Operating Income? | -$9.60M | -$7.57M | -$4.59M | -$4.78M | -$4.48M | -$1.91M | -$1.55M | -$1.54M | -$1.32M | -$586,233 |
| EBITDA? | -$7.29M | -$7.34M | -$4.49M | -$4.72M | -$4.44M | -$1.88M | -$1.53M | -$1.52M | -$1.31M | -$581,134 |
| Income Before Tax | -$14.14M | -$14.24M | -$6.59M | -$4.77M | -$4.45M | -$1.82M | -$1.55M | -$1.54M | -$1.32M | -$586,233 |
| Income Tax Expense | $0 | -$350,256 | -$335,832 | -$614,362 | $23,927 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$14.14M | -$13.89M | -$6.26M | -$4.16M | -$4.45M | -$1.82M | -$1.55M | -$1.54M | -$1.32M | -$586,233 |
| EPS? | $-0.57 | $-0.59 | $-0.28 | $-0.20 | $-0.25 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.00 |
| Diluted EPS? | $-0.57 | $-0.59 | $-0.28 | $-0.20 | $-0.25 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality